-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 20th, the US FDA announced the expansion of the emergency use authorization of Moderna and Pfizer/BioNTech's new crown vaccine, allowing adults over 18 to receive the new crown booster vaccine.
Specifically, this authorization allows adults over the age of 18 to receive a new crown booster vaccine at least 6 months after completing Moderna or Pfizer/BioNTech's new crown vaccination
This authorization is based on the FDA's clinical trial results of these two mRNA vaccines as booster vaccines
In addition, the FDA also evaluated real-world data, including risk data on myocarditis and pericarditis of vaccine recipients
"The new crown vaccine has been proven to be a highly effective means to combat COVID-19
Reference materials:
[1] Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters.